Summary Competition Authority of Bosnia & Herzegovina qualified the actions of the Sarajevo cantonal government that provided preferential treatment to the domestically produced medicines under the national health insurance scheme as anticompetitive practice and ordered it to modify its decisions in this respect. The infringement of the competition law consisted in the cantonal government's decision to replace any foreign medicines by equivalent domestically produced one, which deprived foreign producers and exporters from the benefits of the state reimbursement under the national health insurance scheme. Facts Under the national health insurance scheme  in Bosnia & Herzegovina the cantonal governments established the list of the approved medicines that can be sold to the
The Bosnian & Herzegovinan Competition Authority prosecutes regional Government for intervening with competitive process on the market for pharmaceuticals reimbursed under the national health insurance scheme (Association of Foreign Pharmaceutical Producers in Bosnia & Herzegovina / Cantonal Government Sarajevo)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.